Cannabis Is Finally Failing Like a Real Industry
Cannabis has a receivership problem. That's not the interesting part.
Cannabis is finally failing like a real industry. This is not the obituary it sounds like.
When a cannabis company collapses, the coverage reaches for familiar material. Hubris. Hype. Another casualty of a market that promised more than it delivered. That story is sometimes true. It is also a way of not seeing what is actually happening. Thirty licensed businesses in receivership in Massachusetts as of March, up from 24 in January. More in California. Definitely more on the way. The reflex is to read those numbers as a warning, but they are closer to a milestone.
Every industry that grows up eventually produces ordinary commercial disappointment. Cannabis has, finally, reached that point. What it never built was a way to fail, though.
“Size without margin is just a larger surface area for stress.”
Any business can end up in receivership. Airlines do. Bookstores do. Food trucks do. Hedge funds do. They borrow too much. The market pivots. A lawsuit lands at the wrong moment. A management team sucks at their job. None of that is unique to cannabis. It is just what markets eventually do to companies that run out of runway.
MedMen, Ayr, 4Front…these were not long shots. They had everything the market wanted: scale, capital access, brand recognition. None of it was enough. Size without margin is just a larger surface area for stress.
The difference in cannabis is not why companies fail. It is what happens after they do.
Consider what these companies are actually operating inside. Retail operators routinely face effective tax rates of 50 to 70 percent under Section 280E, which taxes gross profit rather than net income and disallows ordinary business deductions. Massachusetts cannabis prices have fallen more than 66 percent from their 2021 peak. California wholesale prices are down 57 percent in real terms over four years. Meanwhile, roughly 80 percent of all new cannabis capital raised through 2025 came in the form of debt - not equity - at rates that would be unrecognizable in any mainstream consumer goods sector. Remember, equity often requires a background check…the type with fingerprints. Curaleaf refinanced at 11.5 percent in early 2026. Cresco at 12.5. AYR's bridge loan carried a 14 percent coupon. Approximately $6 billion in cannabis debt matures by the end of this year, with the largest operators holding more than half of it.
Bad management absolutely explains some of it. The structure explains the rest. Green Thumb Industries - by most measures the most disciplined major operator in the sector - retains only about 60 cents of every cash flow dollar after 280E obligations. The beer and spirits industry, by comparison, retains 85 to 90. That distance is tax policy, not management’s execution. And when a company built on that kind of disadvantage finally tips over, the law offers almost nothing to catch it.
In a normal industry, distress has an architecture. A company can seek protection, stop the creditor stampede, sort claims, reject contracts, preserve operations, and try to keep some enterprise value alive while everyone argues about the future. In cannabis, those tactics are largely unavailable to plant-touching operators. In re The Hacienda Company, LLC, a 2023 decision from the Central District of California, allowed a former operator that had already exited cannabis to liquidate non-cannabis assets through Chapter 11. It did not, however, extend that pathway to active operators.
When a cannabis company tips into receivership, the issue is far more complex than who gets paid. The issue is who gets control - of the license, the premises, the inventory, the cash, the records, the employees, the track-and-trace account, and the physical product sitting in a vault or on a shelf. In cannabis, those are questions of regulatory accountability and public safety, not just commerce.
The receiver is not stepping into a chain of dry cleaners. The receiver is stepping into a licensed business that may be holding substantial quantities of a product the federal government still treats as contraband. Regulators need to know who is operating, under what authority, and with what accountability. Product cannot become ownerless. Inventory cannot wander out of compliance. The handoff is highly supervised because it has to be.
The asset puzzle adds another layer. A distressed cannabis company may own equipment, inventory, lease rights, real estate, or all four. It may also hold something more valuable and more fragile: a license in a capped market, a workable relationship with a municipality, a built-out compliant facility, a recognizable brand and intellectual property, a strong and well-trained team, a living customer base, and operating systems that someone spent years building. In many cases, that is the real estate of the deal. Almost none of it moves cleanly.
A cannabis business cannot always be sold to the highest bidder because the highest bidder may not qualify. Licenses are not ordinary property. Local approvals may need to be preserved, amended, or rebuilt. A landlord may cooperate, or may decide distress is a useful time to renegotiate from strength. License caps can make an asset look scarce and valuable on paper while quietly, and artificially, narrowing the pool of people who can actually buy it. A receivership can look like restructuring one month and a fire sale the next.
What accelerates that slide is simple: once the creditors move, nothing stops them. When 4Front Ventures entered voluntary receivership in Massachusetts last May, a $40 million refinancing had fallen through just weeks earlier. The company had a viable exit and no automatic stay to preserve it while the deal closed.
The StateHouse proceedings in California make the point at scale. The portfolio was described as one of the largest cannabis receiverships in the country, with more than $120 million in annual sales and a multi-jurisdiction sale process shaped as much by licensing and local approval constraints as by debt itself. Not one failed store. Not one overhyped founder. A regulated portfolio with real operating mass and no clean off-ramp.
“The industry built itself an entrance. It never got around to building an exit.”
But structure can only explain so much. Some of these companies earned their ending. Sloppy operators with no business running a business. Executives who mistook mythology for strategy. Balance sheets that were fiction dressed up as a plan. Snake oil salesman good at investor pitches. The industry built itself an entrance. It never got around to building an exit.
And capital, it turns out, has opinions about that. Investors understand risk. They sign up for it all the time. What they want, especially in a volatile industry, is some confidence about what happens when things go sideways. That is why collateral matters. That is why covenants matter. That is why people like prenups even when they hope never to read them again. The comfort comes from knowing the back-end rules exist. It is best to negotiate your breakup when you still enjoy one another’s company.
The federal reform assumption made that ask easier to accept for a while. Operators and investors were not simply being reckless. Many were explicitly betting that rescheduling would arrive in time to normalize banking, relieve the 280E burden, and open refinancing options before the debt came due. The MedMen receivership estate filed suit in December claiming damages in excess of $1 billion specifically because the company did not survive long enough to see federal reclassification - pointing to a peak market capitalization near $3 billion and licenses covering dozens of retail locations. That lawsuit will go wherever it goes. What it captures, regardless of outcome, is how much of the industry's capital structure was built on a reform timeline that kept not arriving.
That does not make investment impossible. It does, though, make the downside feel less civilized.
Policymakers should take that seriously. Businesses do fail. States cannot prevent that, and they shouldn’t. They do need a process legible enough to preserve value where value still exists, strict enough to maintain real control over licensed inventory, and efficient enough to keep a distressed operator from becoming a second-order compliance problem. States can help themselves by clarifying receivership authority, tightening approval timelines, deciding how local approvals travel in distressed sales, and treating continuity of operations as part of market design rather than as an afterthought.
A federal question sits underneath all of this. As long as plant-touching cannabis companies remain largely outside the ordinary bankruptcy framework, the industry will keep relying on state-law substitutes that do not offer the same predictability or breathing room. Even a partial fix would be difficult - federal policy would still have to reconcile insolvency administration with the ongoing handling of a federally prohibited substance. The contradiction is real, and the system reflects it.
For years, the cannabis conversation was about who got in. Who got licensed. Who got capital. Who got shelf space. Who got the next market. Mature markets are asking a different question now, and it is the more adult one. When a cannabis business fails, what exactly survives, who is allowed to control it, and how does the law move that value without losing the thread?
It is the clearest test yet of whether legalization built a way to fail as well as a way to begin.
